Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2011-08-09

FDA Approved: SAPHRIS — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SAPHRIS (asenapine) submitted by Allergan to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saphris (asenapine)

Snippet

SUPPL AP for SAPHRIS (ASENAPINE MALEATE)